Because solid cancer tumors require an adequate blood supply to grow and metastasize, the inhibition of VEGFR signaling with small molecule drugs such as sorafenib or pazopanib is used as a well-established treatment in various cancers, since tumors cannot grow more than 2 mm without angiogenesis. This evidence concerns the gene KDR and cancer.